

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	1825
Policy Title	Dexrazoxane for preventing cardiotoxicity in children and young people (< 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
Clinical Reference Group	Children and Young Adult Cancer
Which stakeholders were contacted to be involved in policy development?	<p>A policy working group (PWG) was established in line with NHS England's standard policy development practices.</p> <p>The draft policy proposition was sent to the following groups for comment:</p> <ul style="list-style-type: none"> • Children and Young Adult Cancer Services Clinical Reference Group (CRG); and • Registered stakeholders for the Children and Young Adult Cancer Services CRG.
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	<p>Relevant Royal Colleges and professional societies have membership on the Children and Young Adult Cancer Services CRG or are registered stakeholders of the CRG. These include:</p> <ul style="list-style-type: none"> • Royal College of Nursing; • Children's Cancer and Leukaemia Group (CCLG); • Teenage and Young Adults Cancer (TYAC); and • Royal College of Paediatrics and Child Health <p>Named representatives for each of these organisations were sent copies of the draft policy proposition and invited to provide comment.</p>
Which stakeholders have actually been involved?	A response was received from CCLG. In addition, six other responses were received from registered stakeholders including the Royal College of Radiologists and two NHS organisations providing cancer care to children and young people.

<p>Explain reason if there is any difference from previous question</p>	<p>Not applicable.</p>
<p>Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p>	<p>None.</p>
<p>How have stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy proposition was distributed to stakeholders on 29 April 2019, via email for a period of two weeks of stakeholder testing, in preparation for public consultation.</p> <p>Stakeholders were asked to submit their responses via email, using a standard response and in line with NHS England’s standard processes for developing clinical commissioning policies.</p> <p>Stakeholder testing asked the following questions:</p> <ul style="list-style-type: none"> • It is proposed that highly specialised products will go for period of public consultation. Please select the consultation level that you consider to be most appropriate (up to 6 weeks or up to 12 weeks). • Do you have any further comments on the proposed changes to the document? • If Yes, please describe below, in no more than 500 words, any further comments on the proposed changes to the document as part of this initial ‘sense check’. • Please declare any conflict of interests relating to this document or service area.
<p>What has happened or changed as a result of their input?</p>	<p>There were seven responses to stakeholder testing, three of which were from individual clinicians and four of which were from organisations. Four respondents actively supported the draft policy proposition and remaining respondents raised no specific concerns or any disapproval.</p> <p>As a result of stakeholder feedback, one minor clarification point has been made to the “inclusion criteria” included in the draft</p>

	<p>policy proposition. This clarification point ensures that dexrazoxane is given from the start of treatment when the planned dose of anthracycline is expected to meet or exceed the minimum dose threshold, rather than waiting for the dose to be exceeded. Wording throughout the document has also been updated to reflect the use of dexrazoxane when high-dose anthracyclines are planned.</p> <p>No other changes have been made to the policy proposition.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>All stakeholders (including CRG members and registered stakeholders) will be notified when the draft policy proposition goes out to public consultation.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Of the seven responses received, five respondents recommended a public consultation period of up to 6 weeks.</p> <p>Two respondents did not select a preferred timeframe for public consultation.</p> <p>Given the support for the policy at stakeholder testing, the PWG is recommending a 30-day public consultation period.</p>